-
Announces of cubo pharmaceuticals: http://findarticles.com/p/articles/mi_m0EIN/is_2005_August_9/ai_n1487-3142
-
Biron C A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol, 1998, 10: 383-390.
doi: 10.1006/smim.1998.0138
-
Bowden S, Jackson K, Littlejohn M, et al. 2004. Quantification of HBV Covalently Closed Circular DNA from Liver Tissue by Real-Time PCR. In: Hepatitis B and D protocols (Lau J Y N, Hamatake R, eds. ), Volume 1: Detection, Genotypes, and Characterization. Robert K. Hamatake, Johnson Y. N. Lau: HumanaPress, 41-51. ISBN: 1-59259-669-X Series: Methods in Molecular Medicine.
-
Cooksley W G, Piratvisuth T, Lee S D, et al. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B, J Viral Hepat, 2003, 10: 298-305.
doi: 10.1046/j.1365-2893.2003.00450.x
-
De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev, 2003, 16: 569-596.
doi: 10.1128/CMR.16.4.569-596.2003
-
Delaney W E 4th, Edwards R, Colledge D, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 2002, 46: 3057-3060.
doi: 10.1128/AAC.46.9.3057-3060.2002
-
Deres K, Schr der C H, Paessens A, et al.Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 2005, 299: 893-896.
-
Digestive Disease Week, May 19-24, 2007, Washington DC. http://www.hivandhepatitis.com/2007icr/ddw/docs/052507b.html
-
Enzo therapeutics: http://www.enzobio.com/therapeutics/product_pipeline.asp.
-
Hepatitis B fact sheet WHO/204 Geneva: World Health Organization. 2000. http://www.who.int/infs/en/fact204.html (21 December 2005, date last accessed).
-
Jassim S A and Naji M A. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol, 2003, 95: 412-427.
doi: 10.1046/j.1365-2672.2003.02026.x
-
Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J. Antimicrob. Chemother, 2003, 51: 761-785.
doi: 10.1093/jac/dkg163
-
Keeffe E B, Marcellin P. New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5: 285-294.
doi: 10.1016/j.cgh.2006.09.036
-
King R W, Ladner S K, Miller T J, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) beta-L-2', 3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother, 1998, 42: 3179-3186.
-
Kumar R, Agrawal B. Novel treatment options for hepatitis B virus infection. Curr Opin Investig Drugs, 2004, 5: 171-178.
-
Lai C L, Leung N, Teo E K, et al. Telbivudine phase Ⅱ Investigator Group. A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B.Gastroenterology, 2005, 129: 528-536.
doi: 10.1016/j.gastro.2005.05.053
-
Lee H S, Chung Y H, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepato-logy, 2006, 43: 982-988.
-
Liang X F, Chen Y S, Wang X J, et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin J Epidemiol, 2005, 26: 655-660.
-
Liu J, Feitelson MA. 2004. Detection of Hepatitis B Virus X Antigen by Immunohistochemistry and Western Blotting. In: Hepatitis B and D protocols (Lau J Y N, Hamatake R, eds. ), Volume 1: Detection, Genotypes, and Characteri-zation. Robert K. Hamatake, Johnson Y. N. Lau: Humana-Press, 71-84. ISBN: 1-59259-669-X Series: Methods in Molecular Medicine.
-
Li Y F, Wang G F, He P L, et al. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J Med Chem, 2006, 49: 4790-4794.
doi: 10.1021/jm060330f
-
Lok A S F, McMahon B J. AASLD practice guidelines: chronic hepatitis B. Hepatology, 2007, 45:507-539.
doi: 10.1002/hep.v45:2
-
Nelson M. 2003. Telbivudine (L-dT) in phase Ⅲ studies for chronic hepatitis B. Hepdart, December 14-18, Kauai, Hawai.
-
Nie Q H,Zhang J C.2006. A meta-analysis of thymosin-onotherapy for chronic hepatitis B virus infection. Chin J Pract Int Med, 26: 382-386.
-
No author listed. Mismatched double-stranded RNA: polyI: polyC12U. Drugs R D, 2004, 5: 297-304.
doi: 10.2165/00126839-200405050-00006
-
Novartis Pharmaceuticals Corporation: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3365
-
Novelos: http://www.novelos.com
-
Quan D J, Peters M G. Antiviral therapy:nucleotide and nucleoside analogs. Clin Liver Dis, 2004, 8: 371-385.
doi: 10.1016/j.cld.2004.02.012
-
Romero M R, Efferth T, Serrano M A et al. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an “in vitro†replicative system. Antiviral Res, 2005, 68: 75-83.
doi: 10.1016/j.antiviral.2005.07.005
-
Samuel C E. Antiviral actions of interferons. Clin Microbiol Rev, 2001, 14: 778-809.
doi: 10.1128/CMR.14.4.778-809.2001
-
Sorbera L A., Serradell N, Bolos J.Pradefovir Mesilate. Drugs Fut, 2007, 32: 137-143.
doi: 10.1358/dof.2007.032.02.1075008
-
Source Hollis-Eden Pharmaceuticals, Inc. http://phx.corporate-ir.net/phoenix.zhtml?c=113795 & p=irol-newsar-ticle_print & ID=212253
-
Stoeckl L, Funk A, Kopitzki A, et al. Identification of a structural motif crucial for infectivity of hepatitis B viruses. Proc Natl Acad Sci USA, 2006, 103: 6730-6734.
doi: 10.1073/pnas.0509765103
-
Stray S J, Bourne C R, Punna S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA, 2005, 102: 8138-8143.
doi: 10.1073/pnas.0409732102
-
Sullivan S. Pradefovir a promising prodrug for hepatitis B. Meeting report. Inpharma Weekly, 2006, 1521: 7-9, January 21.
-
van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepato-logy, 2004, 40: 1421-1425.
-
van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 2006, 44:318-325.
doi: 10.1002/(ISSN)1527-3350
-
Wolters L M, Hansen B E, Niesters H G, et al. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganci-clovir, Eur J Gastroenterol Hepatol, 2002, 123: 1007-1011.
-
Ying C, Li Y, Leung C H, et al. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA, 2007, 104: 8526-8531.
doi: 10.1073/pnas.0609883104
-
ZADAXIN® (thymosin alpha 1): http://www.scicloneinternational.com/zadaxin.shtml
-
Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of Peginterferons.Semin Liver Dis, 2003, 23: 23-28.
doi: 10.1055/s-2003-41631
-
Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res, 2004, 64: 1-15.
doi: 10.1016/S0166-3542(04)00162-7